This study is recruiting. It focuses on depression and currently lists participation information in the United States.
This study is looking at whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy for people with Parkinson Disease or Depression. Participants receive a study treatment and complete follow-up visits and assessments. Taking part may give some people access to Psilocybin, but direct benefit is not guaranteed.
The official record suggests in-person participation through a university, with sites including University of California, San Francisco. Participation appears to involve assessments along with scans or samples to help researchers understand patterns more clearly. The main fit is usually being able to understand the study and consent and being able to follow the planned visits or tasks, while common reasons not to take part include safety concerns that need urgent care first and other factors that could make participation unsuitable. This is an early-stage study, which usually means a smaller group and a focus on learning how the approach behaves.
This study may matter because it adds public evidence around depression. HopeStage presents it as a starting point for understanding the study, checking the official source, and preparing questions with a care team.
This page links back to the public source record so people can verify details directly with the registry and research team.
If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.
Open source recordThis form records your interest so HopeStage can follow up with practical guidance. It is not a medical eligibility decision and it does not guarantee a study spot.
Taking part may give access to a new approach being evaluated.
It requires regular visits and structured follow-up.
Requires travel, with in-person participation in United States.
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
This study is exploring medication or study treatment for people with depression. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed.
This study is sponsored by Joshua Woolley, MD, PhD. Based on the sponsor name or official registry information, it appears to be an individual investigator. You should verify the details in the official registry record.
This study may involve medication or study treatment, study visits, and assessments. The time commitment is long follow-up or multiple visits. The study phase is not available in HopeStage data. Check the official source record to see whether a phase is listed. Enrollment is not available in HopeStage data. HopeStage cannot say whether a study is safe or right for you. Before joining, ask the research team about possible risks, time commitment, visits, side effects, compensation, safety monitoring, and whether participation may affect your current care.
Use the official source record linked on this page to check the full study description, recruitment status, eligibility criteria, locations, sponsor information, phase, enrollment, contact details, and any listed risks or requirements.